The NIAMS Research Innovation for Scientific Knowledge (RISK) for Musculoskeletal Diseases (R61/R33) initiative focuses on innovative research within the NIAMS mission by encouraging applicants to pursue unusual observations, test imaginative hypotheses, investigate creative concepts, and build ground-breaking paradigms, all of which deviate significantly from the current prevailing theories or practice. This FOA is particularly designed to encourage the submission of projects that are considered too risky, premature, controversial, or unconventional for other NIH mechanisms. This FOA intends to support disease-focused translational studies, up to, but not including, first in human studies. This FOA is not intended to support clinical trials.
The companion FOA (PAR-16-382) encourages X02 applications for the Research Innovation for Scientific Knowledge (RISK) for Musculoskeletal Diseases. The X02 is the recommended (not required) first step in the application process for this FOA. Potential applicants should read both FOAs.
Investigators whose X02 pre-applications are evaluated to be highly innovative and most relevant to the RISK program, will be notified of the opportunity to submit an R61/R33 application to this FOA.